Inhibikase Therapeutics Inc expected to post a loss of 19  cents a share - Earnings Preview

Inhibikase Therapeutics

11/08/2022 02:09

* Inhibikase Therapeutics Inc  IKT.OQ   IKT.O  is expected
to show
a fall in quarterly revenue when it reports  results on August
12. 
    * The Atlanta Georgia-based  company is expected to report 
a
78.0% decrease in revenue to $300 thousand from $1.36 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Inhibikase
Therapeutics
Inc is for a loss of 19 cents per share. For the same quarter
last year, the company reported a loss of 22 cents per share.
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is $6​, above​ its last closing price of $0.86.
​​​

This summary was machine generated August 11 at 01:09 GMT.  All
figures in US dollars  unless otherwise stated